QMed BioTech

Q-Med is a Swedish biotechnology company that pioneered the development of stabilized hyaluronic acid for medical and aesthetic use. Founded in 1987 by Bengt Ågerup, the company is best known for its proprietary NASHA (Non-Animal Stabilized Hyaluronic Acid) technology, which allows for the creation of biocompatible gels with long-lasting effects. Its flagship product, Restylane, became a global leader in the dermal filler market, while other products like Durolane and Deflux addressed needs in orthopedics and urology. In 2011, Q-Med was acquired by Galderma for approximately $1.1 billion, integrating its innovative portfolio into Galderma's global dermatology business. The company's legacy continues through its widely used aesthetic and therapeutic treatments.